The Extended RAS Panel detects the presence of 56 specific mutations in RAS genes (KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4) in the tumor tissue of patients with mCRC. If the Extended RAS Panel result indicates that a mutation is present in the colorectal cancer tissue, then panitumumab is not recommended. If the Extended RAS Panel does not detect a mutation (presumed to be RAS mutation-negative), then panitumumab may be an appropriate treatment
Biopsy specimen / paraffin block required for this test.
Download the free health test app from Dr. B. Lal Clinical Laboratory. Find all the healthcare information and needs you require in just one place. You can schedule home collection, see reports, save medical history, search for more than 1800 tests, and more with just one app. Available both on iOS and Android. Simplify healthcare, download the Dr. B. Lal Clinical Lab App.